PURPOSE: Head-and-neck squamous cell carcinoma (HNSCC) is the fifth most common malignancy worldwide. Alcohol use and tobacco use are the most established risk factors; however, human papilloma virus (HPV) infection is a major risk factor for a subset of HNSCCs. Although HPV-positive tumors typically present at a more advanced stage at diagnosis, they are associated with a better prognosis. Tumor hypoxia confers poor prognosis and treatment failure, but direct tumor oxygen measurement is challenging. Endogenous markers of hypoxia (EMHs) have been proposed but have not replicated the prognostic utility of direct oxygen measurement. The expression of endogenous markers of hypoxia may be influenced by oxygen-independent factors, such as the HPV status of the tumor. METHODS AND MATERIALS: Consecutive cases of locally advanced HNSCC, treated with a uniform regimen of combined radiotherapy and chemotherapy, were identified. Tissue microarrays were assembled from triplicate 0.6-mm cores of archived tumor tissue. HPV status was inferred from semiquantitative p16 immunostaining and directly measured by use of HPV-specific chromogenic in situ hybridization and polymerase chain reaction. Automated quantitative fluorescent immunohistochemistry was conducted to measure epithelial and stromal expression of carbonic anhydrase IX (CAIX) and glucose transporter 1 (GLUT1). RESULTS: High stromal CAIX expression was associated with significantly reduced overall survival (p = 0.03) in patients with p16-negative tumors. CONCLUSIONS: This is the first study to use quantitative immunohistochemistry to examine endogenous markers of hypoxia stratified by tumor p16/HPV status. Assessment of CAIX expression in p16-negative HNSCC could identify patients with the least favorable prognosis and inform therapeutic strategies.
PURPOSE: Head-and-neck squamous cell carcinoma (HNSCC) is the fifth most common malignancy worldwide. Alcohol use and tobacco use are the most established risk factors; however, human papilloma virus (HPV) infection is a major risk factor for a subset of HNSCCs. Although HPV-positive tumors typically present at a more advanced stage at diagnosis, they are associated with a better prognosis. Tumor hypoxia confers poor prognosis and treatment failure, but direct tumoroxygen measurement is challenging. Endogenous markers of hypoxia (EMHs) have been proposed but have not replicated the prognostic utility of direct oxygen measurement. The expression of endogenous markers of hypoxia may be influenced by oxygen-independent factors, such as the HPV status of the tumor. METHODS AND MATERIALS: Consecutive cases of locally advanced HNSCC, treated with a uniform regimen of combined radiotherapy and chemotherapy, were identified. Tissue microarrays were assembled from triplicate 0.6-mm cores of archived tumor tissue. HPV status was inferred from semiquantitative p16 immunostaining and directly measured by use of HPV-specific chromogenic in situ hybridization and polymerase chain reaction. Automated quantitative fluorescent immunohistochemistry was conducted to measure epithelial and stromal expression of carbonic anhydrase IX (CAIX) and glucose transporter 1 (GLUT1). RESULTS: High stromal CAIX expression was associated with significantly reduced overall survival (p = 0.03) in patients with p16-negative tumors. CONCLUSIONS: This is the first study to use quantitative immunohistochemistry to examine endogenous markers of hypoxia stratified by tumorp16/HPV status. Assessment of CAIX expression in p16-negative HNSCC could identify patients with the least favorable prognosis and inform therapeutic strategies.
Authors: Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz Journal: Head Neck Date: 2012-01-27 Impact factor: 3.147
Authors: Marina Domingo-Vidal; Diana Whitaker-Menezes; Cristina Martos-Rus; Patrick Tassone; Christopher M Snyder; Madalina Tuluc; Nancy Philp; Joseph Curry; Ubaldo Martinez-Outschoorn Journal: Mol Cancer Res Date: 2019-06-25 Impact factor: 5.852
Authors: Annette M Lim; Danny Rischin; Richard Fisher; Hongbin Cao; Kathleen Kwok; Daniel Truong; Grant A McArthur; Richard J Young; Amato Giaccia; Lester Peters; Quynh-Thu Le Journal: Clin Cancer Res Date: 2011-11-17 Impact factor: 12.531
Authors: Joseph C Walsh; Artem Lebedev; Edward Aten; Kathleen Madsen; Liane Marciano; Hartmuth C Kolb Journal: Antioxid Redox Signal Date: 2014-05-09 Impact factor: 8.401
Authors: Nils H Nicolay; Nicole Wiedenmann; Michael Mix; Wolfgang A Weber; Martin Werner; Anca L Grosu; Gian Kayser Journal: Eur J Nucl Med Mol Imaging Date: 2019-12-07 Impact factor: 9.236
Authors: Joseph M Curry; Madalina Tuluc; Diana Whitaker-Menezes; Julie A Ames; Archana Anantharaman; Aileen Butera; Benjamin Leiby; David M Cognetti; Federica Sotgia; Michael P Lisanti; Ubaldo E Martinez-Outschoorn Journal: Cell Cycle Date: 2013-04-10 Impact factor: 4.534